Lilly’s Tirzepatide Shows Benefit In Heart Failure, Including Outcomes

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Lilly is the first to demonstrate a benefit on heart failure outcomes with an incretin, even though rival Novo Nordisk already filed heart failure data for Wegovy with the US FDA. 

Lilly's tirzepatide showed a benefit in heart failure • Source: Shutterstock

Eli Lilly and Company reported positive heart failure data for tirzepatide, its blockbuster GIP/GLP-1 agonist, following rival Novo Nordisk A/S, which already showed a benefit in heart failure symptoms with semaglutide. Lilly, however, is the first company to show a benefit on heart failure outcomes with an incretin and tirzepatide also outperformed SGLT-2 inhibitors approved for heart failure on outcomes.

Key Takeaways

  • Lilly’s SUMMIT trial testing tirzepatide is the first incretin drug to show a benefit on heart failure outcomes.

Lilly announced the positive topline results of the Phase III SUMMIT trial on 1 August. Tirzepatide already has FDA approval...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.